Horizon Discovery Group, a specialist in gene editing and gene modulation technologies, has announced the appointment of Terry Pizzie as CEO and board director with immediate effect.
Pizzie joined Horizon Discovery in 2017 as Head of Commercial Operations and has close to 30 years of leadership experience within the biotechnology tools sector.
According to Horizon Discovery, Pizzie's impact has been significant as he has rapidly built a world-class commercial team, recruiting talent from across the industry. His actions have aligned Horizon's commercial teams and allowed them to sell the full Horizon portfolio to all customers across different geographies as well as form teams focused on adding value to key customer accounts.
Dr Ian Gilham, executive chairman of the board of directors at Horizon Discovery, said: "Since joining Horizon, Terry has been instrumental in building a world-class commercial team, and his outstanding leadership and highly valuable commercial experience will help lead the company through its next phase of growth and development as we transition from building scale through acquisitions towards becoming a sustainably profitable business driven by demand for our market-leading products and services in both gene editing and gene modulation."
Prior to joining Horizon, Pizzie worked for Pacific Biosciences, first as VP Europe and later as Head of Global Sales.
Previous leadership roles include Director Global Commercial Operations at Genetix prior to its acquisition by Danaher; and Senior VP Global Commercial Operations at Swedish Biotechnology firm Biacore, where he was part of the team that reignited the company's commercial success, culminating in its acquisition by GE Life Sciences in 2006.
Pizzie started his career at Applied Biosystems in 1988 in a sales role and rose through the ranks to VP Europe in 2003. Pizzie graduated with a degree in Physiology and Biochemistry from the University of Reading.
Terry Pizzie, CEO at Horizon Discovery, said: "Horizon has built a highly successful global business which has a world leading position in gene editing and gene modulation. We are now an established market leader across the high value and high margin RNAi and CRISPR end-markets, which are estimated to be worth £2.2 billion and growing at approximately 20% per year."